CMMI Head Fowler Says Drug Pricing Demos Must Wait For Congress

By John Wilkerson / October 5, 2021 at 3:26 PM
CMS’ innovation center can’t design payment models to test drug price controls until after Congress decides what it’s going to do on drug pricing, Center for Medicare and Medicaid Innovation Director Elizabeth Fowler said Tuesday (Oct. 5), and the center also can’t design demos for Aduhelm until CMS determines a national Medicare coverage policy for the Alzheimer’s drug. HHS’ drug price control plan calls for multiple innovation center demonstrations to control drug prices. They include models that target rebates and...

Not a subscriber? Sign up for 30 days free access to exclusive, detailed reporting on drug pricing reforms, Medicaid policy, FDA news and much more.